Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) Operating Expenses (2019 - 2025)

Avidity Biosciences' Operating Expenses history spans 7 years, with the latest figure at $255.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 105.98% year-over-year to $255.3 million; the TTM value through Dec 2025 reached $764.7 million, up 96.16%, while the annual FY2025 figure was $764.7 million, 96.16% up from the prior year.
  • Operating Expenses reached $255.3 million in Q4 2025 per RNA's latest filing, up from $201.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $255.3 million in Q4 2025 to a low of $26.6 million in Q1 2021.
  • Average Operating Expenses over 5 years is $85.8 million, with a median of $60.6 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 253.77% in 2021, then rose 13.35% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $40.4 million in 2021, then soared by 38.6% to $56.0 million in 2022, then rose by 23.11% to $68.9 million in 2023, then skyrocketed by 79.82% to $124.0 million in 2024, then skyrocketed by 105.98% to $255.3 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Operating Expenses are $255.3 million (Q4 2025), $201.3 million (Q3 2025), and $175.0 million (Q2 2025).